Drug, across the briefings

Venetoclax across 9 cancers

Venetoclax appears in 9 of the briefings; its FDA label names 2 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Acute myeloid leukemia	label names disease	phase 4 on BCL2	173	104
Chronic lymphocytic leukemia	label names disease	phase 4 on BCL2	121	73
Chronic myeloid leukemia		phase 4 on BCL2	12	6
Diffuse large B-cell lymphoma		phase 4 on BCL2	32	11
Follicular lymphoma		phase 4 on BCL2	22	6
Mantle cell lymphoma		phase 4 on BCL2	35	19
Myelodysplastic syndromes		phase 4 on BCL2	106	67
Small cell lung cancer		phase 4 on BCL2	5	1
Waldenström macroglobulinaemia		phase 4 on BCL2	5	5

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.